Abstract: The invention provides a nucleic acid coding for the CGL1 polypeptide with the SEQ ID No 1 amino acid sequence or also fragments or variants of the CGL1 polypeptide. The invention also relates to the use of a nucleic acid such as defined hereinabove for producing a nucleotide probe or primer specific for the normal cgl1 gene or the mutated cgl1 gene. Another object of the invention is also to provide methods for screening a candidate compound interacting with the CGL1 polypeptide or modulating the expression of the cgl1 gene as well as sets or kits for screening such candidate compounds.

Abstract: The present invention is directed to isolated variant nucleic sequence of genomic sequence encoding the translation initiation factor 2 alpha kinase 3 (EIF2AK3) capable of inducing the Wolcott-Rallison syndrome (WRS) or affecting the risk of developing diabetes and/or other pathology related to WRS, and to the polypeptide encoded by these sequences. The invention also relates to vectors or transformned cells containing these sequences. The present invention further concerns method and kit for determining in a subject the risk of developing diabetes and/or other pathology related to WRS and method for selecting compound which can be used as medicament for the prevention and/or treatment of these pathologies.